Stock Technical Report on Sarepta Therapeutics Inc (NASDAQ:SRPT)

Sarepta Therapeutics Inc (NASDAQ:SRPT) (TREND ANALYSIS) shares were traded with a volume more than nine times higher than the usual volume. The stock closed last trading session at $26.24, up by 60.2%, with a volume of 20,041,893 shares against an average volume for the last 3 months of 908,560.

Stock Performance: Click here for a free comprehensive Trend Analysis Report

Sarepta Therapeutics Inc (NASDAQ:SRPT) is currently trading 25.98% below its 52-week-high, 131.6% above its 52-week-low. The 1-year range for the stock is $11.33 – $35.45. Sarepta Therapeutics Inc (SRPT) has a price to book ratio of 3.37 versus Healthcare sector average of 5.88. SRPT stock price has outperformed the Nasdaq by 74.8%. The Therapeutics company is currently valued at $1.09 billion and its share price closed the last trading session at $26.24. The stock has a 50-day moving average of $14.05 and a 200-day moving average of $14.05.

Sarepta Therapeutics Inc (SRPT) current short interest stands at 13.26 million shares. It has increased by 7% from the same period of last month. Around 38% of the company’s shares, which are float, are short sold. With a 10-days average volume of 1.15 million shares, the number of days required to cover the short positions stand at 11.6 days.

SRPT reported last quarter earnings on May 07. The Therapeutics company announced earnings per share of $-1.49 against a consensus Street estimate of $-1, missing estimate by $0.49. This corresponds to a decrease of $0.3 compared to the same quarter of the previous fiscal year.

Is this a Buying Opportunity? Click here for a free Trend Analysis Report

There are currently seventeen analysts that cover SRPT stock. Of those seventeen, seven have a Buy rating, ten have a Hold rating. On a consensus basis this yields to an Overweight rating. The consensus target price stands at $23.5.

A recent analyst activity consisted of Canaccord Genuity upgrading their Hold rating to Buy on May 20. Canaccord Genuity increased their price target on SRPT from $16 to $30. This corresponds to a 14.33% upside from the last closing price. On the date of report, the stock closed at $16.38.

SunTrust Robinson Humphrey upgraded their Neutral rating to Buy on the same day, and increased their price target on SRPT stock from $14 to $33. This corresponds to a 25.76% upside from the last closing price. On the date of report, the stock closed at $16.38.

Another research firm was Baird who upgraded their Neutral rating to Outperform on May 6. On the date of report, the stock closed at $14.76.

Company profile

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of unique RNA-based therapeutics for the treatment of both rare and infectious diseases. The Company offers its products to the medical industry in countries around the world.

Stock Technical Report on Sarepta Therapeutics Inc (NASDAQ:SRPT) was last modified: May 21st, 2015 by Jason Ford